Literature DB >> 18470536

Evaluation of parasiticidal activity of fenbendazole, ivermectin, oxibendazole, and pyrantel pamoate in horse foals with emphasis on ascarids (Parascaris equorum) in field studies on five farms in Central Kentucky in 2007.

E T Lyons1, S C Tolliver, M Ionita, S S Collins.   

Abstract

Horse foals on five farms in Central Kentucky were used in field studies in 2007 evaluating activity of paste formulations of four compounds (fenbendazole-FBZ, ivermectin-IVM, oxibendazole-OBZ, and pyrantel pamoate-PRT) against internal parasites with emphasis on ascarids (Parascaris equorum). It has been well established the last few years that there is widespread resistance of P. equorum to ivermectin. The main purpose of the present research was to obtain current data on ascaridicidal activity of FBZ, OBZ, and PRT; also, to acquire further information on ascarid resistance to ivermectin. Additionally, data were documented on drug activity on small strongyles. Detection of ascarid and strongyle eggs in feces of foals was by a qualitative method (presence or absence) or a quantitative method (eggs per gram of feces). Strongyle eggs all were assumed to be from small strongyles. This is based on fecal cultures from horses on one farm and historic records from horses in this area on excellent deworming programs. A girth tape was used to estimate the body weight of each foal so that the appropriate dose rate of each drug could be given. Many of the foals were used in more than one cycle of treatments. Efficacy of the drugs, administered intraorally, was determined by calculating the average percentage reduction (% red.) of the number of foals passing eggs after vs. before treatment: (1) FBZ at 10 mg/kg was tested on four farms; 76 foals were examined, 50 with ascarid eggs (84% red.) and 62 with strongyle eggs (0% red.); (2) IVM at 200 microg/kg was tested on three farms; 58 foals were examined, 18 with ascarid eggs (0% red.) and 48 with strongyle eggs (100% red.); (3) OBZ at 10 mg/kg was tested on three farms; 181 foals were examined, 78 with ascarid eggs (94% red.) and 79 with strongyle eggs (0% red.); (4) PRT was tested on two farms, one farm at 1x (6.6 mg base/kg); 42 were foals examined, 16 with ascarid eggs (0% red.) and 33 with strongyle eggs (12% red.) and one farm at 2x (13.2 mg base/kg); 18 foals were examined, 13 with ascarid eggs (23% red.) and 15 with strongyle eggs (27% red.).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18470536     DOI: 10.1007/s00436-008-0966-8

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  13 in total

1.  Management of drug-resistant cyathostominosis on a breeding farm in central North Carolina.

Authors:  D Little; J R Flowers; B H Hammerberg; S Y Gardner
Journal:  Equine Vet J       Date:  2003-05       Impact factor: 2.888

2.  Cases of reduced cyathostomin egg-reappearance period and failure of Parascaris equorum egg count reduction following ivermectin treatment as well as survey on pyrantel efficacy on German horse farms.

Authors:  G von Samson-Himmelstjerna; B Fritzen; J Demeler; S Schürmann; K Rohn; T Schnieder; C Epe
Journal:  Vet Parasitol       Date:  2006-11-16       Impact factor: 2.738

3.  Apparent ivermectin resistance of Parascaris equorum in foals in Denmark.

Authors:  H Schougaard; M K Nielsen
Journal:  Vet Rec       Date:  2007-03-31       Impact factor: 2.695

4.  Natural infection with Eimeria leuckarti: prevalence of oocysts in feces of horse foals on several farms in Kentucky during 1986.

Authors:  E T Lyons; J H Drudge; S C Tolliver
Journal:  Am J Vet Res       Date:  1988-01       Impact factor: 1.156

5.  Studies on the development and chemotherapy of larvae of Parascaris equorum (Nematoda: Ascaridoidea) in experimentally and naturally infected foals.

Authors:  E T Lyons; J H Drudge; S C Tolliver
Journal:  J Parasitol       Date:  1976-06       Impact factor: 1.276

6.  Macrocyclic lactone-resistant Parascaris equorum on stud farms in Canada and effectiveness of fenbendazole and pyrantel pamoate.

Authors:  J Owen D Slocombe; Rolph V G de Gannes; Mary C Lake
Journal:  Vet Parasitol       Date:  2006-09-07       Impact factor: 2.738

7.  Efficacy of pyrantel pamoate against a macrocyclic lactone-resistant isolate of Parascaris equorum in horses.

Authors:  Craig R Reinemeyer; Julio C Prado; Eric C Nichols; Alan A Marchiondo
Journal:  Vet Parasitol       Date:  2010-03-04       Impact factor: 2.738

8.  Prevalence of anthelmintic resistant cyathostomes on horse farms.

Authors:  Ray M Kaplan; Thomas R Klei; Eugene T Lyons; Guy Lester; Charles H Courtney; Dennis D French; Sharon C Tolliver; Anand N Vidyashankar; Ying Zhao
Journal:  J Am Vet Med Assoc       Date:  2004-09-15       Impact factor: 1.936

9.  Field studies indicating reduced activity of ivermectin on small strongyles in horses on a farm in Central Kentucky.

Authors:  E T Lyons; S C Tolliver; M Ionita; A Lewellen; S S Collins
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

10.  Identification of foals infected with Parascaris equorum apparently resistant to ivermectin.

Authors:  F Patrick D Hearn; Andrew S Peregrine
Journal:  J Am Vet Med Assoc       Date:  2003-08-15       Impact factor: 1.936

View more
  16 in total

1.  Further evaluation in field tests of the activity of three anthelmintics (fenbendazole, oxibendazole, and pyrantel pamoate) against the ascarid Parascaris equorum in horse foals on eight farms in Central Kentucky (2009-2010).

Authors:  Eugene T Lyons; Sharon C Tolliver; Tetiana A Kuzmina; Sandra S Collins
Journal:  Parasitol Res       Date:  2011-04-16       Impact factor: 2.289

2.  Equine anthelmintics by prescription only?

Authors:  Peter W Physick-Sheard; Andrew S Peregrine; F Patrick D Hearn
Journal:  Can Vet J       Date:  2009-05       Impact factor: 1.008

3.  Characteristics of parasitic egg shedding over a 1-year period in foals and their dams in 2 farms in central Saskatchewan.

Authors:  Elzbieta Misuno; Chris R Clark; Stacy L Anderson; Emily Jenkins; Brent Wagner; Katarzyna Dembek; Lyall Petrie
Journal:  Can Vet J       Date:  2018-03       Impact factor: 1.008

4.  Probable reason why small strongyle EPG counts are returning "early" after ivermectin treatment of horses on a farm in Central Kentucky.

Authors:  E T Lyons; S C Tolliver; S S Collins
Journal:  Parasitol Res       Date:  2008-10-18       Impact factor: 2.289

Review 5.  Anthelmintic resistance in equine nematodes.

Authors:  Jacqueline B Matthews
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-10-25       Impact factor: 4.077

6.  Diagnosis and control of anthelmintic-resistant Parascaris equorum.

Authors:  Craig R Reinemeyer
Journal:  Parasit Vectors       Date:  2009-09-25       Impact factor: 3.876

7.  Anthelmintic resistance in cyathostomin populations from horse yards in Italy, United Kingdom and Germany.

Authors:  Donato Traversa; Georg von Samson-Himmelstjerna; Janina Demeler; Piermarino Milillo; Sandra Schürmann; Helen Barnes; Domenico Otranto; Stefania Perrucci; Antonio Frangipane di Regalbono; Paola Beraldo; Albert Boeckh; Rami Cobb
Journal:  Parasit Vectors       Date:  2009-09-25       Impact factor: 3.876

8.  Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information.

Authors:  Teppei Yamaguchi; Junichi Shimizu; Yuko Oya; Yoshitsugu Horio; Toyoaki Hida
Journal:  Case Rep Oncol       Date:  2021-06-17

9.  SvSXP: a Strongylus vulgaris antigen with potential for prepatent diagnosis.

Authors:  Ulla V Andersen; Daniel K Howe; Sriveny Dangoudoubiyam; Nils Toft; Craig R Reinemeyer; Eugene T Lyons; Susanne N Olsen; Jesper Monrad; Peter Nejsum; Martin K Nielsen
Journal:  Parasit Vectors       Date:  2013-04-04       Impact factor: 3.876

10.  Deep amplicon sequencing of preselected isolates of Parascaris equorum in β-tubulin codons associated with benzimidazole resistance in other nematodes.

Authors:  Eva Tydén; Johan Dahlberg; Olof Karlberg; Johan Höglund
Journal:  Parasit Vectors       Date:  2014-08-29       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.